• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Alkermes plc (Amendment)

    6/28/23 8:00:11 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALKS alert in real time by email
    SC 13D/A 1 brhc20055088_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 15)*

    Alkermes Public Limited Company
    (Name of Issuer)

    Ordinary shares, $0.01 par value
    (Title of Class of Securities)

    G01767105
    (CUSIP Number)

    Mark DiPaolo
    Senior Partner, General Counsel
    Sarissa Capital Management LP
    660 Steamboat Road
    Greenwich, CT 06830
    203-302-2330
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    June 28, 2023
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
     
    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. G01767105
    Page 2 of 4 Pages
    SCHEDULE 13D
    This Amendment No. 15 to Schedule 13D (“Amendment No. 15”) relates to ordinary shares, par value $0.01 per share (“Common Stock” and, such shares, the “Shares”), issued by Alkermes Public Limited Company, a company incorporated under the laws of Ireland (the “Issuer”), and amends the initial statement on Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on May 10, 2021 (the “Initial Schedule 13D”), as amended by Amendment No. 1 to Schedule 13D filed on May 27, 2021, Amendment No. 2 to Schedule 13D filed on September 10, 2021, Amendment No. 3 to Schedule 13D filed on November 19, 2021, Amendment No. 4 to Schedule 13D filed on January 10, 2022, Amendment No. 5 to Schedule 13D filed on July 6, 2022, Amendment No. 6 to Schedule 13D filed on October 7, 2022, Amendment No. 7 to Schedule 13D filed on February 6, 2023, Amendment No. 8 to Schedule 13D filed on June 5, 2023, Amendment No. 9 to Schedule 13D filed on June 12, 2023, Amendment No. 10 to Schedule 13D filed on June 14, 2023, Amendment No. 11 to Schedule 13D filed on June 16, 2023, Amendment No. 12 to Schedule 13D filed on June 21, 2023, Amendment No. 13 to Schedule 13D filed on June 23, 2023 and Amendment No. 14 to Schedule 13D filed on June 27, 2023 (the Initial Schedule 13D, as so amended, the “Schedule 13D”), on behalf of the Reporting Persons, to furnish the additional information set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.

    Item 4.
    Purpose of Transaction.

    Item 4 of the Schedule 13D is hereby amended to include the following:

    On June 28, 2023, Sarissa Capital issued the press release attached as Exhibit 11 hereto.

    Item 7.
    Material to Be Filed as Exhibits.

    Item 7 of the Schedule 13D is hereby amended to include the following:

    Exhibit 11 - Press Release, June 28, 2023


    CUSIP No. G01767105
    Page 3 of 4 Pages
    SCHEDULE 13D
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Dated:  June 28, 2023
     
       
    SARISSA CAPITAL MANAGEMENT LP
     
       
    By:
    /s/ Mark DiPaolo
     
     
    Name: Mark DiPaolo
     
     
    Title: Senior Partner, General Counsel
     
       
    /s/Alexander J. Denner
     
    Alexander J. Denner
     


    CUSIP No. G01767105
    Page 4 of 4 Pages
    SCHEDULE 13D
    INDEX TO EXHIBITS

    Exhibit 1 - Form 8-K of the Issuer filed with the U.S. Securities and Exchange Commission on April 30, 2021 (incorporated by reference in this Schedule 13D)*

    Exhibit 2 - Joint Filing Agreement of the Reporting Persons, dated as of May 10, 2021*

    Exhibit 3 - Press Release, July 6, 2022*

    Exhibit 4 - Press Release, June 5, 2023*

    Exhibit 5 - Press Release, June 9, 2023*

    Exhibit 6 - Press Release, June 13, 2023*

    Exhibit 7 - Press Release, June 15, 2023*

    Exhibit 8 - Press Release, June 20, 2023*

    Exhibit 9 - Press Release, June 22, 2023*

    Exhibit 10 - Press Release, June 26, 2023*

    Exhibit 11 - Press Release, June 28, 2023

    * Previously filed.



    Get the next $ALKS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALKS

    DatePrice TargetRatingAnalyst
    9/26/2025$44.00Sector Perform → Outperform
    RBC Capital Mkts
    9/3/2025$44.00Overweight
    Wells Fargo
    7/15/2025$43.00Buy
    Goldman
    6/17/2025$42.00Neutral → Buy
    UBS
    5/28/2025$45.00Buy
    Needham
    3/13/2025$40.00Sector Perform
    RBC Capital Mkts
    3/4/2025$21.00 → $38.00Sell → Neutral
    UBS
    2/11/2025$40.00Buy
    Deutsche Bank
    More analyst ratings

    $ALKS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alkermes to Participate in Two Upcoming Investor Conferences

    DUBLIN, Nov. 6, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2025 Healthcare ConferenceDate/Time: Thursday, Nov. 13, 2025 at 2:40 p.m. ET (7:40 p.m. GMT) Jefferies Global Healthcare Conference in LondonDate/Time: Wednesday, Nov. 19, 2025 at 11:30 a.m. ET (4:30 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days. About Alkermes plcAlkermes plc (NASDAQ:ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio

    11/6/25 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FORM 8.1(a) & (b) (Opening Position Disclosure)

    DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.     KEY INFORMATION (a)  Full name of discloser: Alkermes plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates:   Use a separate form for each offeror/offeree Avadel Pharmaceuticals plc (d) Is the discl

    11/5/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Reports Third Quarter 2025 Financial Results

    —    Third Quarter Revenues of $394.2 Million — —    GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — —    Company Raises 2025 Financial Expectations — DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving strong revenue growth and robust profitability, fueled by focused execution and underlying demand across our commercial portfolio. We ended the quarter in a strong financial position and have raised our financial outlook for 2025, underscoring the momentum of the business. Our proposed acquisition of Avadel Pharmaceuticals annou

    10/28/25 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alkermes Plc upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Alkermes Plc from Sector Perform to Outperform and set a new price target of $44.00

    9/26/25 7:58:20 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Alkermes Plc with a new price target

    Wells Fargo initiated coverage of Alkermes Plc with a rating of Overweight and set a new price target of $44.00

    9/3/25 8:26:50 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Alkermes Plc with a new price target

    Goldman initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $43.00

    7/15/25 8:39:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP R&D, Chief Medical Officer Hopkinson Craig C. exercised 5,000 units of Ordinary Shares at a strike of $19.34 and sold $273,442 worth of Ordinary Shares (9,000 units at $30.38), decreasing direct ownership by 5% to 69,740 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    11/3/25 4:37:40 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP R&D, Chief Medical Officer Hopkinson Craig C. exercised 5,000 units of Ordinary Shares at a strike of $19.34 and sold $283,776 worth of Ordinary Shares (9,000 units at $31.53), decreasing direct ownership by 5% to 73,740 units (SEC Form 4)

    4 - Alkermes plc. (0001520262) (Issuer)

    10/15/25 6:47:05 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by SVP, Chief Financial Officer Reed Joshua

    4 - Alkermes plc. (0001520262) (Issuer)

    10/10/25 4:41:40 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Alkermes plc

    SCHEDULE 13G - Alkermes plc. (0001520262) (Subject)

    11/10/25 8:14:11 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Alkermes plc

    10-Q - Alkermes plc. (0001520262) (Filer)

    10/28/25 9:20:51 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Alkermes plc. (0001520262) (Filer)

    10/28/25 7:05:26 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Financials

    Live finance-specific insights

    View All

    Alkermes plc Reports Third Quarter 2025 Financial Results

    —    Third Quarter Revenues of $394.2 Million — —    GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — —    Company Raises 2025 Financial Expectations — DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving strong revenue growth and robust profitability, fueled by focused execution and underlying demand across our commercial portfolio. We ended the quarter in a strong financial position and have raised our financial outlook for 2025, underscoring the momentum of the business. Our proposed acquisition of Avadel Pharmaceuticals annou

    10/28/25 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION THIS ANNOUNCEMENT IS BEING MADE PURSUANT TO RULE 2.7 OF THE IRISH TAKEOVER RULES  —     Augments Revenue Growth Profile and Diversifies Alkermes' Commercial Portfolio with New High Growth Product, LUMRYZ™(Sodium Oxybate)—     Accelerates Alkermes' Commercial Entry into Sleep Medicine Market and Provides Strong Foundation for Potential Launch of Alixorexton—     Expected to be Immediately Accretive and Enhance Profitability Upon Closing—     Positions the Combined Organization to Accelerate Inn

    10/22/25 7:00:00 AM ET
    $ALKS
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes to Report Third Quarter Financial Results on October 28, 2025

    DUBLIN, Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Tuesday, Oct. 28, 2025 to discuss the company's third quarter financial results. The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event and may be accessed by visiting Alkermes' website.  About Alkermes plc Alkermes plc (NASDAQ:ALKS), a mid-cap gro

    10/20/25 4:00:00 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Alkermes plc

    SC 13G - Alkermes plc. (0001520262) (Subject)

    11/14/24 1:22:34 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/12/24 1:28:21 PM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Alkermes plc

    SC 13G/A - Alkermes plc. (0001520262) (Subject)

    11/8/24 10:46:38 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALKS
    Leadership Updates

    Live Leadership Updates

    View All

    Alkermes Appoints Joshua Reed as Chief Financial Officer

    DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth," said Mr. Reed.  Mr. Reed brings over 30 years of financial leadership experience, with a strong focu

    9/12/25 9:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

    DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern

    3/7/24 7:00:00 AM ET
    $ALKS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/1/23 6:16:00 PM ET
    $ALK
    $ALKS
    $AWI
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care